Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,244.00+0.48%ETH$2,243.45+1.84%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
AL

NYSE · ALNY

Alnylam Pharmaceuticals, Inc.

Healthcare · Biotechnology

$174.00

Down-$9.00 (-5.17%)

Updated Oct 31, 2026, 12:31 AM

SID Score

4.5/10

Composite research score

Smart Money

47/100

Neutral

Market cap
44.15B
P/E ratio
140.31
Dividend yield
0.00%
52-week range
$172.31 – $482.73
Volume
11.8M
Avg. volume
1.54M

Price performance · ALNY

ALNY price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 29, 2026

ALNY closed at $174.00 after 20 trading sessions, down 20.81% for the selected period.

Last close
$174.00
Period change
-20.81%
Period low
$174.00
Period high
$234.03
Daily close
View OHLC price history
ALNY OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 29, 2026$185.59$202.37$172.31$174.0011.8M
Oct 28, 2026$222.72$232.88$220.00$232.401.94M
Oct 27, 2026$225.00$228.49$222.82$226.791.6M
Oct 26, 2026$226.24$232.48$224.1001$227.661.44M
Oct 23, 2026$227.28$229.39$222.00$224.031.06M
Oct 22, 2026$224.92$229.82$223.76$227.282.21M
Oct 21, 2026$227.86$230.84$224.88$225.101.18M
Oct 20, 2026$237.73$238.96$229.54$230.711.51M
Oct 19, 2026$232.645$236.54$231.255$233.291.34M
Oct 16, 2026$235.18$237.98$231.29$231.831.4M
Oct 15, 2026$230.00$234.30$228.12$234.031.26M
Oct 14, 2026$224.49$229.56$222.25$224.471.11M
Oct 13, 2026$228.93$229.525$221.56$223.821.12M
Oct 12, 2026$233.13$233.60$226.3501$227.02916.92K
Oct 9, 2026$224.74$232.935$222.705$232.68959.45K
Oct 8, 2026$222.03$225.90$218.39$224.531.77M
Oct 7, 2026$224.39$230.42$222.46$224.411.06M
Oct 6, 2026$221.015$229.18$217.18$223.941.36M
Oct 5, 2026$218.36$222.08$215.46$219.891.28M
Oct 2, 2026$231.31$231.36$219.40$219.721.66M

Latest ALNY news

The latest Smart Investors Daily articles mentioning ALNY.

Stock researchCompany · Overview

ALNY research

Overview

Company profile and research snapshot.

Company profile

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway in cells that enables sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$495.36
Implied upside
—
Analysts
20
ALNY recent ratings
DateFirmRatingTarget
Oct 14, 2026Wells FargoEqual-Weight—
Oct 14, 2026CitigroupBuy—
Oct 8, 2026RBC CapitalOutperform—
Sep 30, 2026JP MorganOverweight—
Sep 21, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 23, 2026

Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington’s Disease

CAMBRIDGE, Mass., October 23, 2026--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported positive initial Phase 1b clinical trial results for ALN-HTT02, an investigational RNAi therapeutic in development for the treatment of Huntington’s disease, which will be developed under the International Nonproprietary Name (INN) brezosiran (bre-ZOH-sir-an). The data were presented in oral and poster presentations at the European Huntington’s Disease Network (

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By